Cynthia collins editas
WebAs Former President and Chief Executive Officer at EDITAS MEDICINE INC, Cynthia Collins made $662,427 in total compensation. Of this total $86,538 was received as a salary, $0 was received as a bonus, $0 was received in stock options, $0 was awarded as stock and $575,889 came from other types of compensation. This information is … WebDec 10, 2024 · (Nasdaq: EDIT), a leading genome editing company, today announced …
Cynthia collins editas
Did you know?
WebMar 4, 2024 · AGN-151587 (EDIT-101) is a CRISPR-based experimental medicine under … WebEditas Medicine 2 years 3 months Chief Executive Officer Feb 2024 - Feb 20242 years 1 …
WebAs announced by Editas Medicine Inc. in a news release and in a regulatory filing … WebAs a member of Board of Directorsat EDITAS MEDICINE INC, Cynthia Collinsmade $943,935in total compensation. Of this total $1,834was received as fees earned or paid in cash, $0was received as non-stock incentive plan compensation,
WebApr 13, 2024 · CAMBRIDGE, Mass., April 13, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1. WebView the profiles of people named Cynthia ( Collins. Join Facebook to connect with …
WebAug 6, 2024 · Editas (Nasdaq: EDIT) announced after markets closed Tuesday that Cynthia Collins will stay on in the chief executive role, which she has occupied on an interim basis since January. She joined the ...
WebJan 23, 2024 · In the meantime, Cynthia Collins, a member of the company’s board, will assume the role of interim CEO. Bosley will remain with Editas in an advisory role through the end of the year in order to ensure a smooth transition, the company said. Neither Editas nor Bosley provided a reason in the announcement for her decision to leave the company. razor page redirecttoactionWebOct 7, 2024 · Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer. Aug 6, 2024. Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10. Jul 25, 2024 « Older Entries. Press Coverage. razor page redirectingWebAug 13, 2024 · Editas Medicine CAMBRIDGE, Mass. (GLOBE NEWSWIRE) -- Editas … razor page redirect to actionWebFeb 10, 2024 · Cynthia Collins owns about 43,760 units of Editas Medicine, Inc … simpsons video game xbox oneWebMs. Collins has more than 40 years of leadership experience in cell and gene therapies … razor page redirect to another pageWebAug 6, 2024 · Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, … simpson super bowl prediction bengalsWebJan 9, 2024 · Collins added, “I look forward to working with Michelle, Harry, and the rest of our strong executive team as progress through the clinical trial for EDIT-101, advance our pipeline, and execute on our bold vision to develop transformative, durable medicines for people living with serious diseases.” razor page redirect to current page